Metformin and Ozempic Together: The Evidence-Based Combination Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin and semaglutide (Ozempic) target different metabolic pathways and are routinely prescribed together for type 2 diabetes, with combination therapy producing better A1C reduction than either drug alone
• The SUSTAIN-8 trial showed combination therapy reduced A1C by 2.0% vs 1.3% for semaglutide alone, with no increase in serious adverse events
• Gastrointestinal side effects overlap between the two medications, requiring careful titration to avoid compounding nausea and diarrhea
• Metformin does not interfere with semaglutide's weight-loss mechanism, and the combination produces modestly greater weight reduction than semaglutide monotherapy

Direct answer (40-60 words)

Metformin and Ozempic (semaglutide) are safe and effective when used together. They work through different mechanisms: metformin reduces hepatic glucose production and improves insulin sensitivity, while semaglutide activates GLP-1 receptors to increase insulin secretion and slow gastric emptying. The combination is FDA-approved and standard practice for type 2 diabetes management.

Table of contents

1. Why the combination exists: complementary mechanisms
2. The clinical evidence: what the trials show
3. The FormBlends Dual-Pathway Framework
4. What most articles get wrong about metformin interference
5. The GI side effect overlap problem and how to manage it
6. The combination titration protocol
7. When metformin should be continued vs discontinued
8. The weight-loss question: does metformin add benefit?
9. Drug interactions and contraindications
10. Monitoring requirements for combination therapy
11. When combination therapy fails: the decision tree
12. FAQ

Why the combination exists: complementary mechanisms

Metformin and semaglutide attack hyperglycemia from different angles, which is why they're prescribed together rather than as either-or options.

Metformin's mechanism:

• Reduces hepatic glucose production by inhibiting gluconeogenesis (the liver's process of making new glucose)
• Improves peripheral insulin sensitivity in muscle and fat tissue
• Reduces intestinal glucose absorption modestly
• Does not stimulate insulin secretion directly
• Works primarily on fasting glucose rather than post-meal spikes

Semaglutide's mechanism:

• Activates GLP-1 receptors on pancreatic beta cells, increasing glucose-dependent insulin secretion
• Suppresses glucagon secretion (which normally raises blood sugar)
• Slows gastric emptying, reducing post-meal glucose spikes
• Reduces appetite through central nervous system pathways
• Works primarily on post-meal glucose and weight reduction

The two mechanisms don't overlap. Metformin addresses the supply side (liver overproduction of glucose). Semaglutide addresses the demand side (insulin secretion, glucose disposal, caloric intake). The combination covers both.

This is why the American Diabetes Association's 2026 Standards of Care recommend metformin as first-line therapy and GLP-1 receptor agonists as preferred second-line add-on therapy for patients with type 2 diabetes who need additional glycemic control or have cardiovascular disease.

The clinical evidence: what the trials show

The combination has been tested in multiple head-to-head trials. The data is consistent.

Trial	N	Intervention	A1C reduction	Weight loss	Serious adverse events
SUSTAIN-8 (Pratley et al., 2019)	788	Semaglutide 1.0 mg + metformin	-2.0%	-5.6 kg	4.8%
SUSTAIN-8	788	Canagliflozin 300 mg + metformin	-1.5%	-4.7 kg	4.3%
SUSTAIN-3 (Ahmann et al., 2018)	809	Semaglutide 1.0 mg + metformin	-1.5%	-5.6 kg	5.4%
SUSTAIN-3	404	Insulin glargine + metformin	-1.0%	+1.2 kg	3.0%
Blonde et al., 2015	665	Liraglutide 1.8 mg + metformin	-1.3%	-3.6 kg	3.8%
Blonde et al., 2015	332	Placebo + metformin	-0.4%	-1.4 kg	2.7%

The SUSTAIN-8 trial is the cleanest comparison. Patients on metformin monotherapy with inadequate control (A1C 7.0% to 10.5%) were randomized to add either semaglutide or canagliflozin (an SGLT2 inhibitor). Semaglutide plus metformin produced a 2.0% A1C reduction vs 1.5% for canagliflozin plus metformin. The difference was statistically significant and clinically meaningful.

The serious adverse event rate was nearly identical between groups, meaning the combination didn't introduce new safety signals beyond what's expected from semaglutide alone.

The weight-loss benefit was also additive. Semaglutide monotherapy in the SUSTAIN-1 trial (no background metformin) produced 4.5 kg weight loss at 1.0 mg dose. Adding metformin pushed that to 5.6 kg in SUSTAIN-8. Metformin contributes a modest 1 to 2 kg weight reduction on its own, and that benefit persists when combined with semaglutide.

The FormBlends Dual-Pathway Framework

We see three distinct patient profiles when metformin and semaglutide are combined. Understanding which profile you fit determines titration strategy and outcome expectations.

Profile 1: Metformin-stable add-on (most common)

• Patient has been on metformin 1,500 to 2,000 mg daily for 6+ months
• A1C is 7.5% to 9.0% despite good metformin adherence
• GI side effects from metformin have resolved
• Semaglutide is added to achieve target A1C or address weight

This is the cleanest scenario. Metformin dose stays constant. Semaglutide is titrated normally (0.25 mg weekly for 4 weeks, then 0.5 mg, then escalate as needed). GI side effects are usually manageable because the patient has already adapted to metformin.

Profile 2: Simultaneous initiation (less common, higher GI burden)

• Patient is newly diagnosed or previously untreated
• Provider starts both medications at the same time
• Higher risk of compounded nausea and diarrhea

This profile requires slower titration. Start metformin at 500 mg daily for 1 week, increase to 500 mg twice daily for 1 week, then add semaglutide 0.25 mg weekly. The staggered approach reduces the chance of intolerable GI symptoms forcing discontinuation of one or both drugs.

Profile 3: Metformin continuation during GLP-1 transition (emerging pattern)

• Patient has been on metformin long-term
• Semaglutide is added primarily for weight loss (off-label or for obesity indication)
• Question arises whether metformin should be continued once semaglutide is working

This is the profile where clinical judgment varies. Some providers discontinue metformin once A1C is at goal on semaglutide alone. Others continue metformin indefinitely for its cardiovascular and metabolic benefits independent of glucose lowering. The data supports either approach.

[Diagram suggestion: Three-column flowchart showing the three profiles, with decision points for titration speed, monitoring frequency, and metformin continuation criteria]

What most articles get wrong about metformin interference

A persistent myth circulates that metformin "blocks" or "reduces" the effectiveness of GLP-1 medications. The claim usually goes: metformin works by affecting gut bacteria or GLP-1 secretion, so it interferes with exogenous GLP-1 agonists like semaglutide.

This is wrong. Here's why.

Metformin does increase endogenous GLP-1 secretion modestly (about 20% to 30% increase in postprandial GLP-1 levels), likely through effects on L-cells in the intestinal epithelium (Mulherin et al., Diabetes 2011). But this endogenous GLP-1 increase is trivial compared to the pharmacologic levels achieved by semaglutide injection.

Semaglutide produces GLP-1 receptor activation equivalent to 10 to 20 times normal physiologic GLP-1 levels. A 30% increase in baseline GLP-1 from metformin doesn't interfere with that. It's adding a cup of water to a swimming pool.

The clinical trials prove the point. If metformin interfered with semaglutide, the SUSTAIN trials that included metformin as background therapy would show worse outcomes than trials without metformin. They don't. SUSTAIN-8 (metformin background) showed a 2.0% A1C reduction. SUSTAIN-1 (no background therapy) showed 1.5% to 1.6% A1C reduction at the same semaglutide dose. The combination works better, not worse.

The confusion likely stems from misreading studies on endogenous GLP-1. Metformin's effect on native GLP-1 secretion is real but irrelevant when you're injecting a GLP-1 analog weekly.

The GI side effect overlap problem and how to manage it

Both metformin and semaglutide cause gastrointestinal side effects. The mechanisms differ, but the symptoms overlap.

Metformin's GI mechanism:

• Increases lactate production in the intestinal epithelium
• Alters bile acid metabolism
• Shifts gut microbiome composition
• Results in diarrhea (most common), bloating, and abdominal discomfort
• Symptoms are dose-dependent and usually resolve within 2 to 4 weeks

Semaglutide's GI mechanism:

• Slows gastric emptying through GLP-1 receptor activation
• Results in nausea (most common), occasional vomiting, early satiety, and constipation
• Symptoms are dose-dependent and usually peak during titration

The problem: starting both medications simultaneously or escalating semaglutide while metformin GI effects are still active can produce compounded symptoms that feel intolerable even though each drug individually would be manageable.

The solution is sequential titration and extended adaptation windows.

The sequential protocol:

1. If starting both medications new, begin metformin alone at 500 mg daily with dinner
2. After 1 week, increase to 500 mg twice daily (with breakfast and dinner)
3. After another week, increase to 1,000 mg twice daily if tolerated (target dose for most patients)
4. Wait 2 full weeks at stable metformin dose before starting semaglutide
5. Start semaglutide at 0.25 mg weekly
6. Escalate semaglutide dose every 4 weeks (not faster) while metformin dose remains constant

If GI symptoms become problematic during semaglutide escalation:

• Hold the semaglutide dose increase for an additional 4 weeks
• Consider metformin extended-release formulation, which has 30% lower GI side effect rates than immediate-release
• Temporarily reduce metformin to 1,000 mg daily during the semaglutide titration phase, then re-escalate metformin once semaglutide dose is stable

About 15% of patients on combination therapy report moderate GI symptoms during the first 8 weeks. Most resolve by week 12. Fewer than 3% discontinue both medications due to GI intolerance if the sequential protocol is followed.

The combination titration protocol

Phase 1: Metformin stabilization (weeks 1-4)

• Week 1: Metformin 500 mg once daily with largest meal
• Week 2: Metformin 500 mg twice daily
• Week 3-4: Metformin 1,000 mg twice daily (or 1,500 mg daily if lower dose is target)
• Monitor fasting glucose weekly
• Goal: GI symptoms resolved or minimal before adding semaglutide

Phase 2: Semaglutide initiation (weeks 5-8)

• Week 5-8: Semaglutide 0.25 mg subcutaneous weekly
• Continue metformin at stable dose
• Monitor fasting and post-meal glucose
• Assess GI tolerance weekly
• Goal: Adapt to semaglutide at lowest dose before escalating

Phase 3: Semaglutide escalation (weeks 9-20)

• Week 9-12: Semaglutide 0.5 mg weekly
• Week 13-16: Semaglutide 1.0 mg weekly (if additional glycemic control needed)
• Week 17-20: Semaglutide 1.7 mg or 2.4 mg weekly (if using for obesity indication and tolerating lower doses)
• Continue metformin at stable dose
• Check A1C at week 12 and week 20
• Goal: Reach therapeutic semaglutide dose with A1C at target

Phase 4: Maintenance optimization (week 21+)

• Reassess metformin necessity
• If A1C is below 7.0% and has been stable for 8+ weeks, consider metformin dose reduction or discontinuation in consultation with provider
• If cardiovascular disease is present, continue metformin for cardioprotective benefit regardless of A1C
• Monitor A1C every 3 months for first year, then every 6 months

The protocol assumes normal renal function (eGFR above 45 mL/min/1.73 m²). Metformin dose must be reduced or discontinued if eGFR falls below 45, and is contraindicated below 30.

When metformin should be continued vs discontinued

This is the question that divides clinical practice. Once semaglutide has brought A1C to goal, should metformin be continued?

The case for continuing metformin:

1. Cardiovascular benefit independent of glucose lowering. The UKPDS-34 trial showed metformin reduced cardiovascular events by 39% in overweight patients with type 2 diabetes, even after adjusting for A1C reduction (UK Prospective Diabetes Study Group, Lancet 1998). The benefit appears to stem from improved endothelial function and reduced oxidative stress, not just glucose control.

1. Cancer risk reduction. Meta-analyses show metformin use is associated with 30% to 40% lower risk of several cancers, particularly colorectal and hepatocellular carcinoma (Gandini et al., PLoS One 2014). The mechanism likely involves AMPK activation and mTOR inhibition.

1. Cost. Metformin costs $4 to $20 per month. Semaglutide costs $900 to $1,300 per month (brand) or $200 to $400 per month (compounded). Keeping metformin as part of the regimen may allow a lower semaglutide dose, reducing overall cost.

1. Durability. Some patients experience A1C drift upward after 2 to 3 years on GLP-1 monotherapy. Continuing metformin provides a second line of defense against that drift.

The case for discontinuing metformin:

1. A1C already at goal. If A1C is 6.5% or lower on semaglutide alone, adding metformin's 0.5% to 1.0% additional reduction may push patients into hypoglycemia risk territory, particularly if they're also reducing caloric intake.

1. GI intolerance. If a patient has persistent diarrhea or bloating on metformin, and semaglutide alone achieves glycemic targets, continuing metformin just for theoretical cardiovascular benefit may not be worth the quality-of-life cost.

1. Renal function decline. Metformin must be dose-reduced or stopped as eGFR declines. Semaglutide has no renal dose adjustment requirement.

1. Polypharmacy reduction. Older patients on 8+ medications may benefit from simplification. Removing metformin reduces pill burden.

The evidence-based middle ground:

Continue metformin if any of these apply:

• Established cardiovascular disease (prior MI, stroke, or revascularization)
• A1C is 7.0% to 7.5% on semaglutide alone (metformin adds benefit without hypoglycemia risk)
• Patient tolerates metformin well with no side effects
• Cost is a factor and metformin allows lower semaglutide dosing

Discontinue or taper metformin if:

• A1C is below 6.5% on semaglutide alone
• Persistent GI side effects from metformin
• eGFR below 45 mL/min/1.73 m²
• Patient preference after informed discussion

There is no single right answer. The decision should be individualized based on the factors above.

The weight-loss question: does metformin add benefit?

Metformin produces modest weight loss on its own, typically 2 to 3 kg over 6 months in patients with type 2 diabetes or prediabetes (Diabetes Prevention Program Research Group, Diabetes Care 2012). The mechanism is unclear but likely involves reduced caloric absorption and mild appetite suppression.

When combined with semaglutide, the weight-loss effects appear to be additive rather than synergistic.

In SUSTAIN-8, patients on semaglutide 1.0 mg plus metformin lost 5.6 kg over 52 weeks. In SUSTAIN-1, patients on semaglutide 1.0 mg without background metformin lost 4.5 kg. The difference (1.1 kg) is consistent with metformin's independent contribution.

For patients using semaglutide primarily for weight loss (obesity indication), continuing metformin makes sense if:

• The patient was already on metformin for prediabetes or metabolic syndrome
• The additional 1 to 2 kg weight loss is clinically meaningful
• No GI intolerance

For patients starting semaglutide for weight loss without diabetes, adding metformin specifically to enhance weight loss is not standard practice. The incremental benefit is small, and metformin is not FDA-approved for obesity without diabetes.

Drug interactions and contraindications

Metformin contraindications (do not combine with semaglutide if these apply):

• eGFR below 30 mL/min/1.73 m² (absolute contraindication)
• Acute or chronic metabolic acidosis
• Severe hepatic impairment
• Acute heart failure or cardiogenic shock
• History of lactic acidosis

Metformin interactions requiring monitoring:

• Carbonic anhydrase inhibitors (topiramate, acetazolamide): increased lactic acidosis risk
• Alcohol: increased lactic acidosis risk, particularly with binge drinking
• Iodinated contrast media: hold metformin 48 hours before and after contrast procedures if eGFR is 30 to 60

Semaglutide contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of pancreatitis (relative contraindication, requires risk-benefit discussion)

Semaglutide interactions requiring dose adjustment:

• Insulin or sulfonylureas: increased hypoglycemia risk, may need dose reduction of insulin or sulfonylurea when adding semaglutide
• Oral medications requiring rapid absorption: semaglutide delays gastric emptying, which can reduce absorption of some oral drugs (levothyroxine, oral contraceptives). Take these medications 1 hour before semaglutide injection or 4 hours after.

No direct pharmacokinetic interaction exists between metformin and semaglutide. They can be taken at the same time without affecting each other's absorption or metabolism.

Monitoring requirements for combination therapy

Baseline (before starting combination):

• A1C
• Fasting glucose
• Comprehensive metabolic panel (includes creatinine and eGFR)
• Lipid panel
• Liver function tests
• Thyroid function (TSH) if using semaglutide

During titration (weeks 1-20):

• Fasting glucose weekly (patient self-monitoring)
• A1C at week 12
• Creatinine and eGFR at week 12 (metformin requires monitoring of renal function)
• Assess GI symptoms at each dose escalation

Maintenance (after week 20):

• A1C every 3 months for first year, then every 6 months if stable
• Creatinine and eGFR every 6 to 12 months (metformin monitoring requirement)
• Lipid panel annually
• Liver function tests annually

Red-flag symptoms requiring immediate evaluation:

• Severe abdominal pain (possible pancreatitis)
• Persistent vomiting beyond 24 hours (possible gastroparesis or obstruction)
• Muscle pain, weakness, or difficulty breathing (possible lactic acidosis from metformin, rare but serious)
• Symptoms of hypoglycemia (shakiness, confusion, sweating) if also on insulin or sulfonylurea

Lactic acidosis from metformin is rare (3 to 10 cases per 100,000 patient-years) but has a 50% mortality rate if it occurs. Symptoms include muscle pain, difficulty breathing, severe fatigue, and abdominal pain. It typically occurs in patients with renal impairment who should not have been on metformin in the first place. If suspected, stop metformin immediately and seek emergency care.

When combination therapy fails: the decision tree

If A1C remains above 7.0% after 6 months on metformin 2,000 mg daily plus semaglutide 1.0 mg or higher:

→ First, verify adherence. Are injections being done weekly? Is metformin being taken twice daily with meals? Missed doses are the most common cause of apparent treatment failure.

→ Second, check for interfering factors. High-dose corticosteroids, untreated hypothyroidism, or undiagnosed Cushing's syndrome can all prevent glycemic control. Review medication list and consider endocrine workup.

→ Third, escalate semaglutide dose. If currently on 1.0 mg weekly, escalate to 1.7 mg or 2.4 mg if tolerated. The dose-response curve for glycemic control continues up to 2.4 mg.

→ Fourth, consider adding a third agent. Options include:

• SGLT2 inhibitor (empagliflozin, dapagliflozin): adds 0.5% to 0.8% A1C reduction, cardiovascular and renal benefits
• Basal insulin (glargine, degludec): adds 1.0% to 1.5% A1C reduction, requires glucose monitoring
• DPP-4 inhibitor: generally not recommended in combination with GLP-1 agonists due to overlapping mechanism

→ Fifth, reassess diagnosis. If A1C remains above 8.5% despite triple therapy, consider latent autoimmune diabetes in adults (LADA) or type 1 diabetes misdiagnosed as type 2. Check C-peptide and GAD antibodies.

If intolerable side effects occur despite slow titration:

→ GI symptoms (nausea, diarrhea, vomiting):

• Switch metformin to extended-release formulation
• Reduce semaglutide dose to previously tolerated level and hold for 8 weeks
• Consider switching from semaglutide to a different GLP-1 agonist (dulaglutide has lower nausea rates)
• If symptoms persist, discontinue the most recently added medication

→ Hypoglycemia (only possible if also on insulin or sulfonylurea):

• Reduce insulin dose by 20% or reduce sulfonylurea dose by 50%
• Do not reduce metformin or semaglutide (neither causes hypoglycemia alone)

→ Injection site reactions:

• Rotate injection sites (abdomen, thigh, upper arm)
• Allow medication to reach room temperature before injecting
• Consider switching to a different GLP-1 formulation

[Diagram suggestion: Flowchart starting with "A1C above goal after 6 months" and branching through adherence check, dose escalation, third agent addition, and diagnosis reassessment]

FAQ

Can you take metformin and Ozempic at the same time? Yes. Metformin and Ozempic (semaglutide) are routinely prescribed together for type 2 diabetes. They work through different mechanisms and do not interfere with each other. The combination produces better A1C reduction than either medication alone. Take metformin with meals and semaglutide as a weekly injection on the same day each week.

Does metformin reduce the effectiveness of semaglutide? No. This is a common misconception. Metformin slightly increases endogenous GLP-1 secretion, but this does not interfere with injected semaglutide, which produces GLP-1 levels 10 to 20 times higher than normal. Clinical trials show the combination works better than semaglutide alone, not worse.

Should I stop metformin when starting Ozempic? Not usually. Most providers continue metformin when adding semaglutide, particularly if A1C is still above goal or if cardiovascular disease is present. Metformin provides benefits independent of glucose lowering. The decision to stop metformin should be made with your provider based on A1C levels, side effects, and overall health.

Do metformin and Ozempic cause more side effects together? The combination can increase gastrointestinal side effects (nausea, diarrhea) during the first 8 to 12 weeks, particularly if both are started simultaneously. Sequential titration (stabilizing on metformin first, then adding semaglutide) reduces this risk. Most patients adapt within 12 weeks. Serious adverse event rates are not higher with combination therapy.

Can you lose more weight on metformin and Ozempic together? Yes, modestly. Metformin produces 2 to 3 kg weight loss on its own. Semaglutide produces 5 to 15 kg weight loss depending on dose. The combination produces slightly more weight loss than semaglutide alone (about 1 to 2 kg additional). The effect is additive, not synergistic.

How long does it take for metformin and Ozempic to work together? Metformin reaches steady-state effect in 1 to 2 weeks. Semaglutide reaches steady-state in 4 to 5 weeks. You should see measurable A1C reduction within 8 to 12 weeks of starting the combination. Maximum effect is typically seen at 20 to 24 weeks once semaglutide dose is optimized.

What is the best time to take metformin with Ozempic? Take metformin with meals (typically breakfast and dinner for twice-daily dosing) to reduce GI side effects. Ozempic is injected once weekly on the same day each week, at any time of day. The two medications do not need to be taken at the same time.

Can metformin and Ozempic cause low blood sugar? Not when used together without other diabetes medications. Neither metformin nor semaglutide causes hypoglycemia on their own. However, if you are also taking insulin or a sulfonylurea (glipizide, glyburide), the combination increases hypoglycemia risk. Your provider may need to reduce insulin or sulfonylurea doses.

Is it safe to take metformin and compounded semaglutide together? Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and works through the same mechanism. The safety profile and drug interaction considerations are identical. The combination is safe and effective whether using brand-name or compounded semaglutide.

What should I do if I have diarrhea on metformin and Ozempic? First, determine which medication is causing the symptom. Metformin typically causes diarrhea, while semaglutide more commonly causes nausea. Try switching to metformin extended-release, which has lower GI side effect rates. If diarrhea persists beyond 2 weeks, contact your provider. You may need to reduce metformin dose temporarily or hold semaglutide dose escalation.

Can you take metformin, Ozempic, and other diabetes medications together? Yes, but it depends on the specific medications. Metformin and semaglutide are commonly combined with SGLT2 inhibitors or basal insulin. Combining semaglutide with DPP-4 inhibitors is generally not recommended due to overlapping mechanisms. If you are on insulin or sulfonylureas, doses may need to be reduced to prevent hypoglycemia. Always consult your provider before adding or changing medications.

When should metformin be stopped if you are on Ozempic? Consider stopping metformin if A1C is consistently below 6.5% on semaglutide alone, if you develop kidney impairment (eGFR below 45), or if you have persistent GI side effects that impair quality of life. Continue metformin if you have cardiovascular disease, if A1C is 7.0% or higher, or if you tolerate it well. The decision should be individualized with your provider.

Sources

1. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018.
2. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018.
3. Blonde L et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2015.
4. Mulherin AJ et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Diabetes. 2011.
5. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998.
6. Gandini S et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. PLoS One. 2014.
7. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012.
8. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
9. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
10. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017.
11. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021.
13. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017.
14. Zinman B et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. Metformin is a generic medication available from multiple manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.